638 results on '"Geisbert, Thomas W."'
Search Results
2. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus
3. Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects
4. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
5. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein
6. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease
7. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
8. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.
9. Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever
10. Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
11. Combination therapy protects macaques against advanced Marburg virus disease
12. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
13. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
14. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
15. High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection
16. Animal Models for Henipavirus Research
17. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus
18. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
19. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
20. The Host Response to Smallpox: Analysis of the Gene Expression Program in Peripheral Blood Cells in a Nonhuman Primate Model
21. Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection
22. Reverse Genetics with a Full-Length Infectious cDNA of Severe Acute Respiratory Syndrome Coronavirus
23. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
24. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase
25. Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
26. Immune correlates of postexposure vaccine protection against Marburg virus
27. Rational design of universal immunotherapy for TfR1-tropic arenaviruses
28. Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model
29. Antibodies periodically wax and wane in survivors of Ebola
30. siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease
31. Monoclonal antibody therapy for Junin virus infection
32. Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever
33. Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants
34. Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats
35. Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection
36. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
37. An introduction to the Marburg virus vaccine consortium, MARVAC
38. Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials
39. A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.
40. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever
41. Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques
42. Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic
43. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge
44. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
45. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
46. Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates
47. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
48. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus
49. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates
50. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.